Bajaj Healthcare Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27).

Financial Performance Highlights

  • Revenue from operations: ₹165.6 crore, up 11.3% YoY from ₹148.84 crore in Q1 FY26 and up 8.2% sequentially from ₹153.06 crore in Q4 FY26
  • Gross profit: ₹80.4 crore, up 16.2% YoY from ₹69.13 crore in Q1 FY26
  • Gross margin: 48.3%, expanded from 46.2% in Q1 FY26 and 47.8% in Q4 FY26
  • EBITDA: ₹29.6 crore, up 16.4% YoY from ₹25.39 crore in Q1 FY26
  • EBITDA margin: 17.8%, improved from 17.0% in Q1 FY26 and 16.7% in Q4 FY26
  • Profit after tax (before exceptional items): ₹13.7 crore, up 15.8% YoY from ₹11.83 crore in Q1 FY26 and up 31.8% sequentially from ₹10.4 crore in Q4 FY26
  • PAT margin: 8.3%, improved from 8.0% in Q1 FY26 and 6.8% in Q4 FY26

Business Segment Performance

API — Domestic
  • Sales: ₹92.3 crore, up approximately 27% YoY from ₹72.6 crore in Q1 FY26
  • Performance driven by strong volume growth across key products
API — Exports
  • Sales: ₹50.1 crore, down 4.1% YoY from ₹52.2 crore in Q1 FY26
  • Decline attributed to temporary disruptions from geopolitical situation in West Asia
Formulations
  • Revenue: ₹23.3 crore, down 3.1% YoY from ₹24.1 crore in Q1 FY26
  • Company expects performance to normalize as FY27 progresses

Quarterly Business Updates

  • Bajaj Healthcare became the first Indian company to secure SEC recommendation for manufacture and marketing of Cenobamate Tablets, a next-generation anti-seizure medication for treatment of partial-onset seizures in adults
  • Filed two CEP (Certificate of Suitability to the European Pharmacopoeia) applications during the quarter
  • Cumulative CEP filings now stand at twelve, with eight approved and four under review
  • Expanded state-of-the-art R&D Centre at Savli has become operational, enhancing product development and process innovation capabilities

Management Commentary

Mr. Anil Jain, Managing Director, commented:

  • Commenced FY27 on a positive note with healthy growth across key financial parameters
  • Improved product mix contributed to gross margin expansion
  • API division delivered strong performance with 14.0% YoY growth and 13.5% sequential growth
  • Formulations segment expected to normalize as FY27 progresses and market conditions improve
  • Progressing well towards commercialization of Cenobamate Tablets following regulatory milestone
  • Committed to delivering sustainable growth and enhancing long-term shareholder value

Earnings Call Details

  • Date: July 21, 2026
  • Time: 4:00 PM IST
  • Audio Conference: Universal Dial-In: +91 22 6280 1550 / +91 22 7115 8378
  • International Toll Free: Hong Kong: 800964448, UK: 08081011573, Singapore: 8001012045, USA: 18667462133
  • Pre-registration: Available through provided link
  • Webcast: Details available on Company's website www.bajajhealth.com
  • Transcript will be made available on Company's website following the call

Comparative Financial Data (₹ in crore)

| Metric | Q1 FY27 | Q1 FY26 | YoY % | Q4 FY26 | QoQ % | FY26 |

| API — Exports | 50.1 | 52.2 | (4.1%) | 38.5 | 29.9% | 188.1 |

| Formulations | 23.3 | 24.1 | (3.1%) | 27.7 | (15.8%) | 103.3 |

| Revenue from Operations | 165.6 | 148.8 | 11.3% | 153.1 | 8.2% | 611.0 |

| Gross Profit | 80.4 | 69.1 | 16.2% | 74.5 | 7.8% | 301.8 |

| Gross Margin (%) | 48.3% | 46.2% | | 47.8% | | 48.8% |

| EBITDA | 29.6 | 25.4 | 16.4% | 25.6 | 15.3% | 112.0 |

| EBITDA Margin (%) | 17.8% | 17.0% | | 16.7% | | 18.3% |

| PAT* | 13.7 | 11.8 | 15.8% | 10.4 | 31.8% | 49.0 |

| PAT Margin | 8.3% | 8.0% | | 6.8% | | 8.0% |

*PAT is before exceptional items

Company Background

Bajaj Healthcare Limited is a leading manufacturer of APIs, Intermediates and Formulations, established in 1993. The company operates state-of-the-art manufacturing facilities serving regulated and emerging markets across Europe, USA, Australia, Middle East, and South America.

Contacts

  • Investor Relations: MUFG Intime India Private Limited - Ms. Prachi Ambre, Mr. Irfan Raeen